Skip to main content

View full-text article in PMC

. 2020 Jun 9;18:118–125. doi: 10.1016/j.omto.2020.06.007

Table 2.

Stratification Analysis for Association between WTAP Gene Genotypes and Hepatoblastoma Susceptibility

Variables	rs1853259 (Case/Control)		AOR (95% CI)^a	p^a	rs7766006 (Case/Control)		AOR (95% CI)^a	p^a	Risk Genotypes (Case/Control)		AOR (95% CI)^a	p^a
	AA/AG	GG			GG	GT/TT			0–1	2
Age, Month

<17	128/555	37/86	1.85 (1.20–2.85)	0.005	73/207	92/434	0.60 (0.43–0.85)	0.005	93/435	72/206	1.63 (1.15–2.31)	0.006
≥17	124/680	21/122	0.95 (0.58–1.57)	0.840	52/272	93/530	0.90 (0.62–1.31)	0.593	97/531	48/271	0.98 (0.67–1.43)	0.930

Gender

Female	106/517	21/78	1.31 (0.78–2.22)	0.310	49/175	78/420	0.66 (0.45–0.99)	0.044	80/420	47/175	1.41 (0.94–2.11)	0.094
Male	146/718	37/130	1.40 (0.93–2.10)	0.106	76/304	107/544	0.78 (0.56–1.08)	0.133	110/546	73/302	1.21 (0.87–1.68)	0.256

Clinical Stages

I + II	129/1,235	31/208	1.43 (0.94–2.18)	0.094	68/479	92/964	0.67 (0.48–0.93)	0.017	95/966	65/477	1.40 (1.00–1.95)	0.051
III + IV	79/1,235	10/208	0.75 (0.38–1.47)	0.395	31/479	58/964	0.94 (0.60–1.48)	0.788	60/966	29/477	0.97 (0.61–1.53)	0.892

The results were in bold if the 95% confidence intervals (CIs) excluded 1, or p values were less than 0.05. AOR, adjusted odds ratio.

^a

Adjusted for age and gender, omitting the corresponding stratify factor.